Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy

Annals of Oncology

Volumn 20, Issue 3, 2009, Pages 526-533

  Ennishi, D ^a,b   Yokoyama, M ^a   Terui, Y ^a   Asai, H ^a   Sakajiri, S ^a   Mishima, Y ^a   Takahashi, S ^a   Komatsu, H ^b   Ikeda, K ^b   Takeuchi, K ^c   Tanimoto, M ^b   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Diffuse large B cell lymphoma; Rituximab; Soluble interleukin 2 receptor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMOHOMA; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE;

EID: 61649088127     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn677     Document Type: Article

References (30)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. IARC press 2001.
2. TIN-HsLPF. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
3. Gause A, Jung W, Schmits R et al. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann Oncol 1992; 3 (Suppl 4): 49-52.
4. Chilosi M, Semenzato G, Cetto G et al. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: Relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987; 70: 1530-1535.
5. Wagner DK, Kiwanuka J, Edwards BK et al. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 1987; 5: 1262-1274.
6. Kamihira S, Atogami S, Sohda H et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 1994; 73: 2753-2758.
7. Niitsu N, Iijima K, Chizuka A. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 2001; 66: 24-30.
8. Nakase K, Tsuji K, Tamaki S et al. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect Prev 2005; 29: 256-259.
9. Takeshita T, Asao H, Ohtani K et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992; 257: 379-382.
10. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 1990; 113: 619-627.
11. Smith KA. Interleukin-2: Inception, impact, and implications. Science 1988; 240: 1169-1176.
12. Voss SD, Sondel PM, Robb RJ. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: Association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R. J Exp Med 1992; 176: 531-541.
13. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
14. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
15. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
16. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
17. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
18. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.
19. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive nonHodgkin's lymphoma. Blood 1997; 90: 244-251.
20. Barrans SL, O'Connor SJ, Evans PA et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117: 322-332.
21. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
22. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood 2006; 107: 4207-4213.
23. Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935.
24. Wilson H, Pittaluga S, O'Connor P. Rituximab may overcome Bcl-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphomas [abstract]. Blood 2001; 98: 343a.
25. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
26. Ogura M, Morishima Y, Kagami Y et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 2006; 97: 305-312.
27. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874.
28. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-2143.
29. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric antiCD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65: 264-276.
30. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995-1007.